Caribou Biosciences, Inc. Share Price
CRBUCaribou Biosciences, Inc. Stock Performance
Open $1.95 | Prev. Close $1.96 | Circuit Range N/A |
Day Range $1.95 - $2.00 | Year Range $0.71 - $3.54 | Volume 60,259 |
Average Traded $1.97 |
Caribou Biosciences, Inc. Share Price Chart
About Caribou Biosciences, Inc.
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Caribou Biosciences, Inc. Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
08-Apr-26 | $1.99 | $1.96 | +5.11% |
07-Apr-26 | $1.92 | $1.86 | -4.37% |
06-Apr-26 | $1.98 | $1.95 | +0.52% |
02-Apr-26 | $1.91 | $1.94 | -2.27% |
01-Apr-26 | $1.97 | $1.98 | +4.21% |
31-Mar-26 | $1.86 | $1.90 | +10.47% |
30-Mar-26 | $1.76 | $1.72 | -3.91% |